Volume 18, Issue 1 (4-2015)                   J Arak Uni Med Sci 2015, 18(1): 24-31 | Back to browse issues page

XML Persian Abstract Print


1- Department of ENT, Arak University of Medical Sciences, Arak, Iran
2- Department of Pediatrics, Arak University of medical sciences, Arak, Iran
3- Department of Psychiatrics, Arak University of medical sciences, Arak, Iran
4- Department of ENT, Arak University of Medical Sciences, Arak, Iran , Nedasalehjafari@yahoo.com
5- Department of Statistics, Arak University of medical sciences, Arak, Iran
6- Arak University of medical sciences, Arak, Iran
Abstract:   (21814 Views)

Background: Allergic rhinitis is a common disease which is present in 20% of general population. Major symptoms include sneezing, rhinorrhea, nasal congestion, and nasal pruritus. It seems that tricyclic antidepressants blocking histamine receptors may be used as an effective treatment in allergic rhinitis.

Materials and Methods: In this clinical trial study, 84 patients with allergic rhinitis entered the study and randomly divided into two groups. Patients of 1st group received cetirizine and 2nd group received doxepin for 2 weeks. After 2 weeks patients were evaluated about sneezing, rhinorrhea, nasal congestion, and nasal pruritus.

Results: The results of our study showed that clinical score of patients after 2 weeks was not different in both groups (p=0.261). The only symptom that was affected by the kind of treatment and was significantly different between groups was sneezing (p=0.005).

Conclusion: It seems that there is not much difference in using cetirizine and doxepin in treatment of seasonal allergic rhinitis sympotoms. It is recommended that future studies use TCAs with more potent blocking anti-histamine receptors feature and on more samples.

Full-Text [PDF 578 kb]   (4079 Downloads)    
Type of Study: Original Atricle | Subject: Surgery
Received: 2013/06/21 | Accepted: 2014/12/20

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.